OT-1096 is a first-in-class small molecule with potential to treat advanced metastatic diseases including triple-negative breast cancer. OT-1096 is differentiated from approved targeted therapies as well as immune checkpoint inhibitors (ICI) in both mode of action and efficacy. Our lead candidate affects the anti-tumor immunity via modulating the redox pathway and tumor microenvironment. This has been shown in preclinical in vivo studies using syngeneic and humanized triple-negative breast cancer (TNBC) models. While TNBC is the lead indication, given the potential involvement of the pathway in other diseases, the goal is to extend treatment into other types of cancers in the future.
Breast cancer is the most common cancer in women. Triple-negative breast cancer (TNBC) is an aggressive subgroup characterized by the lack of over-expression of the human epidermal growth factor 2 (HER2) in addition to the absence of progesterone and estrogen receptors. Unlike hormone positive and HER2 positive breast cancers, there are no effective targeted therapies for TNBC. According to WHO estimate, over two million people were diagnosed with breast cancer in 2020 with ~700,000 succumbing to the disease worldwide: of them, around 10-20% would historically be TNBC.
TNBC is highly heterogeneous and often recur after initial response to standard of care chemotherapies. Recurrent and metastatic TNBC has very few effective treatment options. In general, the prognosis of TNBC is very poor and the median survival of patients with metastatic disease is less than 12 months.